Plus Therapeutics is pleased to announce the successful completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss next steps in the clinical development of REYOBIQ™ for the treatment of leptomeningeal metastases (LM).
This meeting marked an important milestone in the advancement of REYOBIQ and resulted in a constructive and collaborative discussion with the FDA regarding key elements of a potential pivotal clinical trial design in LM. The dialogue reflects continued regulatory engagement as Plus Therapeutics works to address an area of significant unmet medical need for patients with central nervous system cancers.
Advancing Toward a Pivotal Clinical Trial
Based on the feedback received during the Type B meeting, Plus Therapeutics (Nasdaq: PSTV) plans to incorporate FDA input into its ongoing dose optimization trial. The company intends to seek further alignment with the FDA on a revised clinical protocol, likely later this year.
The current dose optimization study is designed to refine treatment parameters and inform the design of a future pivotal trial. Upon completion of this study, Plus Therapeutics aims to be positioned to move efficiently into a potential pivotal clinical trial evaluating REYOBIQ in patients with LM.
Addressing a High Unmet Need in Leptomeningeal Metastases
Leptomeningeal metastases occur when cancer spreads to the membranes surrounding the brain and spinal cord. Patients diagnosed with LM face limited treatment options and poor prognoses, underscoring the urgent need for novel therapeutic approaches.
REYOBIQ™ is being developed to address the unique challenges of treating cancers within the central nervous system. Plus Therapeutics’ clinical strategy reflects a commitment to advancing innovative radiotherapeutic solutions designed to improve outcomes for patients with complex and difficult‑to‑treat malignancies.
A Deliberate and Disciplined Path Forward
“Our goal is to be ready for a potential pivotal trial following completion of the current dose optimization study,” the company noted, “and ultimately to work toward the potential approval of REYOBIQ for patients affected by leptomeningeal metastases.”
The completion of the FDA Type B meeting represents a meaningful step forward in this process and reinforces Plus Therapeutics’ focus on regulatory alignment, scientific rigor, and patient‑centered development.
Learn More
- Full press release: https://lnkd.in/gQsWgDJN
- More about REYOBIQ™: https://lnkd.in/gfzNNz49
Plus Therapeutics remains dedicated to advancing innovative therapies for patients facing some of the most challenging cancers and looks forward to sharing further updates as the REYOBIQ clinical program progresses.
Recent Comments